Resiliency Training for Patients With NF2 Via Videoconferencing With Skype

Status Completed

Clinical Trial Summary

The aim of this study is to determine, whether the 3RP is feasible, accepted and efficacious and durable when delivered via Skype to patients with neurofibromatosis type 2 (NF2) who are deaf or have severe hearing loss using Communication Access Realtime Translation (CART) and/or American Sign Language (ASL).

This will be a substudy of the IRB-approved protocol #2013P002605. It is the same study except it is looking at a particular sub-population: patients with NF2 who are hard of hearing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02811718
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	N/A
Start date	July 2016
Completion date	July 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03617276` - Reliability of Functional Outcome Measures in Neurofibromatosis 2
Active, not recruiting	`NCT00973739` - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Completed	`NCT00030043` - An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors	Phase 1
Recruiting	`NCT05685836` - 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Completed	`NCT00004437` - Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2	Phase 2
Recruiting	`NCT03406208` - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing	N/A
Active, not recruiting	`NCT03095248` - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Phase 2
Completed	`NCT02298270` - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype	N/A
Recruiting	`NCT01885767` - Neurofibromatosis (NF) Registry Portal
Completed	`NCT00863122` - Concentration and Activity of Lapatinib in Vestibular Schwannomas	Early Phase 1
Recruiting	`NCT03079999` - Study of Aspirin in Patients With Vestibular Schwannoma	Phase 2
Terminated	`NCT00911248` - PTC299 for Treatment of Neurofibromatosis Type 2	Phase 2
Enrolling by invitation	`NCT04890132` - Vestibular Precision: Physiology & Pathophysiology	N/A
Completed	`NCT01490476` - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients	Phase 2
Active, not recruiting	`NCT00004483` - NF2 Natural History Consortium	N/A
Recruiting	`NCT03893643` - Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Active, not recruiting	`NCT04283669` - Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas	Phase 2
Completed	`NCT02831257` - AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	Phase 2